CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Stereotactic Ablative Radiotherapy for the Treatment of Oligometastatic Cancer

Last updated: March 30, 2021
Project Number: HT0029-000
Research Type: Device
Project Status: In Progress
Result type: Report
Expected Completion Date: March 22, 2021

Stereotactic ablative body radiotherapy (SABR) is a newer form of radiation treatment that delivers high doses to specific body sites over a shorter treatment period than conventional radiotherapy. For cancer therapy, including oligometastatic cancer, SABR is a non-invasive alternative to surgical treatment and an option for patients who are medically inoperable. However, there is a need to determine which patients should be treated with SABR to achieve the greatest benefit and how their disease should be managed. To inform decision-making on the expanded use of SABR in Canada, CADTH is undertaking a Health Technology Assessment (HTA).

As part of this HTA, a clinical review was completed regarding the effectiveness and safety of SABR, with or without standard care, for the treatment of oligometastatic cancer. This review will be regularly updated according to a living systematic review approach. CADTH is also undertaking an Environmental Scan of implementation considerations that will contribute to this HTA to further support decision-making.